Myocardial gene therapy

Jeffrey M. Isner
Additional contact information
Jeffrey M. Isner: Vascular Medicine, and Cardiovascular Research, St Elizabeth's Medical Center, Tufts School of Medicine

Nature, 2002, vol. 415, issue 6868, 234-239

Abstract: Abstract Gene therapy is proving likely to be a viable alternative to conventional therapies in coronary artery disease and heart failure. Phase 1 clinical trials indicate high levels of safety and clinical benefits with gene therapy using angiogenic growth factors in myocardial ischaemia. Although gene therapy for heart failure is still at the pre-clinical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expression may elicit functional improvement in affected individuals.

Date: 2002
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/415234a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:415:y:2002:i:6868:d:10.1038_415234a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/415234a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().